Posts by Mourabit Halima

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy (CTI) Conference was held in Hangzhou, China, bringing together leading global experts, scholars, and industry leaders in the field of cell and immunotherapy. This conference served not only as a platform for academic exchange but also as a vital window to showcase cutting-edge research and drive advancements in the field. Dr. Peihua Lu, a pioneer in CAR-T clinical trials and a leader at Beijing Lu Daopei Hospital, shared groundbreaking progress on CAR-T therapies for T-cell malignancies at CTI 2024, following earlier presentations on CD7 CAR-T therapy for T-ALL/LBL at The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024)  meeting. In an exclusive interview with Hematology Frontier, Professor Lu discussed strategies for applying CAR-T therapy across different types and stages of T-cell malignancies, China’s role in global CAR-T research, and the importance of international collaboration.

In the battle against breast cancer, every physician is a bold explorer, extending the boundaries of life through innovation and dedication. Their efforts not only save lives in the clinic but also drive progress in research, contributing to more precise and effective treatments for breast cancer patients. During the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Oncology Frontier interviewed Dr. Wenxing Qin from Fudan University Shanghai Cancer Center. Professor Qin shared insights into the latest advancements in breast cancer research and treatment, as well as his experience attending the CCHIO. With profound clinical expertise and sharp scientific acumen, he discussed breakthroughs in molecular profiling and personalized treatment strategies for refractory breast cancer, shedding light on future directions in the field.

Breast cancer remains a major threat to women’s health, with continuous advancements in treatment strategies being a focal point for the medical community. In China, as the concept of precision medicine gains momentum, systematic breast cancer treatment is gradually moving towards more personalized and precise approaches. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) during the Breast Oncology Integrative Rehabilitation session, Dr. Man Li from The Second Hospital of Dalian Medical University delivered a presentation titled “Current Status and Advances in Systematic Breast Cancer Treatment in China”, offering an overview of treatment strategies for different subtypes of breast cancer. In an interview with Oncology Frontier, Professor Li discussed the challenges facing systematic treatment and the future directions of breast cancer therapy, emphasizing the transformative role of precision medicine in shaping treatment paradigms.

Breast cancer remains a major threat to women’s health, and early screening plays a crucial role in reducing both incidence and mortality. However, compared to developed countries in Europe and North America, China still faces numerous challenges in breast cancer screening. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) during the Breast Oncology Integrative Rehabilitation session, Dr. Nanlin Li from Xijing Hospital of the Air Force Medical University delivered a report titled “Strategies and Gaps in Breast Cancer Screening for Chinese Women”, providing an in-depth analysis of the current state of breast cancer screening in China and the challenges faced. In an interview with Oncology Frontier, Professor Li highlighted that while progress has been made in recent years, obstacles such as the large population size, insufficient funding, a shortage of trained personnel, and low public awareness continue to limit the full implementation of screening efforts. He called on more women to recognize the importance of screening and encouraged collective efforts from governments and society to improve coverage and safeguard women's health.

Editor's Note:Enhanced Recovery After Surgery (ERAS) represents a cornerstone concept in modern perioperative management. It employs a series of evidence-based interventions designed to mitigate or alleviate the body's stress responses,…

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Summit (AOS), hosted by the Chinese Anti-Cancer Association (CACA) in collaboration with the Chinese Academy of Integrative Medicine and the Shaanxi Anti-Cancer Association, took place from November 14–17 in the ancient city of Xi'an. This prestigious event featured specialized summits co-organized by CACA and global cancer organizations, including the National Comprehensive Cancer Network (NCCN), Union for International Cancer Control (UICC), Society of Latin American and Caribbean Oncology (SLACOM), and International Society of Breast Disease (SIS), to foster international collaboration in cancer prevention and treatment.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain, where several significant advances in lung cancer research were presented. Dr. Antonio Passaro from the European Institute of Oncology Division of Thoracic Oncology in Milan, Italy, shared insights on the safety and antitumor activity of Zipalertinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations. Oncology Frontier had the opportunity to interview Professor Passaro on-site, where he discussed the latest advances in EGFR-targeted therapies.

The PERLA trial results demonstrated that Dostarlimab plus chemotherapy achieved better overall survival (OS) compared to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer (NSCLC), with a median OS of 20.2 months vs. 15.9 months.